TP53 and breast cancer: BAG2-mediated mutant p53 aggregation inhibits the mitochondrial apoptosis pathway, leading to chemoresistance in breast cancer cells, and HSP90 inhibitor (IPI-504) can relieve BAG2-mediated mutant p53 aggregation [17].